K-PLAN

K-Plan is a French company that develops advanced diagnostic solutions, focusing on biological testing kits designed to perform in challenging environmental conditions across various sectors, including public health and industrial applications. Founded in 2007 in Villeurbanne, France, K-Plan specializes in tailored diagnostic solutions. The company raised EUR 497,670 in Series A funding in May 2014, valuing it at EUR 1. 52 million post-money, with participation from Sigma Gestion and Crédit Agricole Corporate and Investment Bank.

K-Plan specializes in the development of tailored diagnostic solutions designed for challenging field conditions. The company's core product offerings include innovative biological testing kits that are engineered to function effectively in various adverse environments, catering primarily to sectors such as environmental monitoring, public health, and industrial applications. These diagnostic tools are designed to provide accurate and timely results, enabling end-users, including government agencies, healthcare providers, and research institutions, to make informed decisions in real-time. K-Plan's products are distributed across several geographical markets, particularly in Europe and North Africa, where demand for reliable field diagnostics is on the rise.

In addition to their primary products, K-Plan also offers comprehensive support services that guide clients through every phase of their projects, from conception to implementation. K-Plan's revenue model is structured around direct business-to-business transactions, wherein the company collaborates with clients in a range of sectors, including public institutions and private enterprises. The sales process involves customized agreements that align with the specific needs of clients, often incorporating bulk orders and long-term contracts for ongoing supply. Revenue is generated through the sale of diagnostic solutions and associated services, which may include training and technical support.

The company’s flagship products, recognized for their reliability and effectiveness, are central to these transactions. Pricing structures for these products reflect the specialized nature of the solutions offered, encompassing both one-time purchases and recurring service agreements tailored to the requirements of the client base. K-Plan plans to leverage the EUR 497,670 raised during the Series A round in May 2014 to enhance its product line and expand into new markets. The funding will support the development of upcoming diagnostic products tailored for adverse field conditions, with targeted launches in 2025.

Additionally, K-Plan aims to enter new geographic markets, specifically targeting expansion into North America by 2026. This strategic approach is focused on diversifying their reach and increasing market presence in regions where demand for effective diagnostic solutions is anticipated to grow.